Astellas Pharma Inc. has been actively involved in significant business developments featuring restructuring, expansion, and collaboration initiatives. Patient access and engagement have been a focus, as shown by their new Life Sciences Center in Cambridge, Massachusetts aimed at expediting breakthrough therapies discovery. The pharma company reported analysts' earnings misses though also projected an impressive 290% profit increase. Additionally, a $2.2bn gene therapy deal was secured with AviadoBio Ltd. Trouble arose in China with an Astellas employee facing indictment by Chinese prosecutors. Collaborations for cell therapy manufacturing with
YASKAWA and on genomic medicines for neurological diseases with
Sangamo Therapeutics are significant. However, negative outlooks also emerged, with investors continuing to face losses and slowdown is reported for their eye drug Izervay after regulatory obstacles. The U.S. FDA approval for Izervay and VYLOY for advanced gastric, GEJ cancer, and geographic atrophy is positive, but Astellas' position remains volatile.
Astellas Pharma Inc. News Analytics from Thu, 10 Aug 2023 07:00:00 GMT to Fri, 25 Apr 2025 11:35:56 GMT -
Rating -3
- Innovation 0
- Information 6
- Rumor -1
